Integra LifeSciences (IART) Reports Mixed Q2 Earnings; Revises Q3/Q4/FY08 Guidance
More News related to IART
- Integra LifeSciences Reports Third Quarter 2008 Financial Results
- Integra LifeSciences to Present At Two Conferences in November
- Children of Chicago Get Free 'Helmets 4 Safety'
- Integra LifeSciences Featured in Forbes 2008 List of 200 Best Small Companies
- Integra LifeSciences Launches Accell Evo3, the Next Generation Accell Technology
More News related to Earnings
- The Elmira Savings Bank, FSB and First Citizens National Bank Announce Consummation of Branch Deal
- Teamsters Tell Elton Brand of Philadelphia 76ers: Don't Tread on Workers with Nike Sneakers
- Fannie Mae Holds 21st Annual Help the Homeless Walkathon
- American Apparel Opens First Manhattan Beach, CA Location
- Pennsylvania National Guard Soldiers Returning From Sinai Peninsula
Integra LifeSciences Holdings Corporation (Nasdaq: IART) reports Q2 adj-EPS of $0.49, 3 cents better than the analyst estimate of $0.46. Revenues for the quarter were $157.2 million, versus the consensus of $159.15 million.
Revises its Q3, Q4 and FY08 adj-EPS guidance to $0.44-$0.49, $0.60-$0.65 and $2.05-$2.15, respectively. The Street estimates are for EPS of $0.48 in Q3 and $2.06 in FY08.
Integra LifeSciences Holdings Corporation engages in the development, manufacture, and marketing of surgical implants and medical instruments used primarily in neurosurgery, extremity reconstruction, orthopedics, and general surgery.
Related Categories
EarningsGuidance
Stocks Mentioned
-0.23Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
